VERIMMUNE INC.
Anti-Tumor Immune Redirection (AIR) therapeutic platform that reprograms existing immune memory against pathogens or vaccines to recognize and attack cancer cells
- Sector
- Biotech
- Headquarters
- BETHESDA, MD
- Founded
- 2019
- Latest Form D
- $4.5M, Sep 2024
- Total capital
- $5.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $5.9M
- 2 Form D · last Sep 2024
- 25 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 7 pending · first 2022
- Rank in peer group#28 of 326
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$4.5M
- Private capital raisedForm D · SEC · 1st filing$1.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#28 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- CHE KOH HSUDirectorNamed in SEC Form D filings
- CYNTHIA WEIYUAN POHDirectorNamed in SEC Form D filings
- HAOLIN SUNGDirectorNamed in SEC Form D filings
- JOHN WEIYUAN TROYERExecutive OfficerNamed in SEC Form D filings
- JOSHUA WEIYUAN WANGExecutive Officer, Director, PromoterNamed in SEC Form D filings
- KEVIN KOH RONGSHENGDirectorNamed in SEC Form D filings
Show all 8 people
- MARTA KOH NEWDirectorNamed in SEC Form D filings
- ROGER KOH POMERANTZDirectorNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 13- GrantedConjugated Virus-like Particles And Uses Thereof As Anti-tumor Immune RedirectorsUSPTOUS 12,528,839
- GrantedVirus-inspired Compositions And Methods Of Redirecting Preexisting Immune Responses Using The Same For Treatment Of CancerUSPTOUS 12,344,637
- PendingChimeric Virus-like Particles And Uses Thereof As Antigen-specific Redirectors Of Immune ResponsesUSPTOApplication 18621631
Show all 13 patent records
- Conjugated Virus-like Particles And Uses Thereof As Anti-tumor Immune RedirectorsJan 20, 2026 · US 12,528,839Granted
- Virus-inspired Compositions And Methods Of Redirecting Preexisting Immune Responses Using The Same For Treatment Of CancerJul 1, 2025 · US 12,344,637Granted
- Chimeric Virus-like Particles And Uses Thereof As Antigen-specific Redirectors Of Immune ResponsesNov 28, 2024 · Application 18621631Pending
- Chimeric Virus-like Particles And Uses Thereof As Antigen-specific Redirectors Of Immune ResponsesApr 2, 2024 · US 11,944,677Granted
- Virus-inspired Compositions And Methods Of Redirecting Preexisting Immune Responses Using The Same For Treatment Of CancerJan 2, 2024 · US 11,858,964Granted
- Conjugated Virus-like Particles And Uses Thereof As Anti-tumor Immune RedirectorsJan 24, 2023 · US 11,560,408Granted
- Chimeric Virus-like Particles And Uses Thereof As Antigen-specific Redirectors Of Immune ResponsesMar 29, 2022 · US 11,285,203Granted
- Virus-inspired Compositions And Methods Of Redirecting Preexisting Immune Responses Using The Same For Treatment Of CancerApplication PCTUS2021055676Pending
- Virus Inspired Compositions And Methods Of Redirecting Preexisting Immune Responses Using Same For Treatment Of CancerApplication 63220485Pending
- Virus Inspired Compositions And Methods Of Redirecting Preexisting Immune Responses Using Same For Treatment Of CancerApplication 63093525Pending
- Conjugated Virus-like Particles And Uses Thereof As Anti-tumor Immune RedirectorsApplication PCTUS2019068619Pending
- Virus-inspired Combinations Against CancerApplication 63471418Pending
- Virus-inspired Compositions, Checkpoint Inhibition, And Methods Of Redirecting Preexisting Immune Responses For Treatment Of CancerApplication 63600580Pending
Related companies, and why
- PathoVaxShares a founder: Joshua Wang
- JPT America, Inc.Similar federal contract value in Biotech · null in contracts
- Scale-Up International Inc.Similar federal contract value in Biotech · null in contracts
- Tetragenetics, Inc.Similar federal contract value in Biotech · null in contracts
- D2G ONCOLOGY, INC.Similar federal contract value in Biotech · null in contracts
- BLR BIO, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .